Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status

Title
Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status
Author(s)
배영경김애리신형찬김민경강수환이수정이은희[이은희]
Keywords
TOPOISOMERASE-II-ALPHA; IN-SITU HYBRIDIZATION; OF-AMERICAN-PATHOLOGISTS; GENE AMPLIFICATION; ADJUVANT CHEMOTHERAPY; CARCINOMA; POLYSOMY; RESPONSIVENESS; SENSITIVITY; VALIDATION
Issue Date
201203
Publisher
KOREAN BREAST CANCER SOC
Citation
JOURNAL OF BREAST CANCER, v.15, no.1, pp.24 - 33
Abstract
Purpose: This study aimed to investigate the clinical significance of chromosome 17 centromere (CEP17) multiplication (increased copy number of CEP17) related to human epidermal growth factor receptor 2 (HER2) and topoisomerase II alpha (TOP2A) status in patients with invasive breast cancer. Methods: We constructed tissue microarrays using 594 invasive breast cancer samples and performed single-color silver-enhanced in situ hybridization (SISH) assay for HER2, TOP2A, and CEP17 to assess for copy number aberrations. The association of CEP17 multiplication with patient survival was analyzed according to HER2 and TOP2A status. Results: Among 567 informative cases, HER2 amplification was noted in 22.8%, TOP2A amplification in 8.3% and TOP2A deletion in 11.1%. CEP17 multiplication was identified in 33.2% and was significantly associated with worse overall survival (OS) (p=0.02) and disease-free survival (DFS) (p=0.02). CEP17 multiplication correlated with patient survival in patients with normal TOP2A or non-amplified HER2 status, but the prognostic significance was lost in those with altered TOP2A or amplified HER2. On multivariate analyses, CEP17 multiplication was an independent prognostic factor for poorer OS (p=0.02) and DFS (p=0.01) in patients with normal TOP2A and non-amplified HER2. Conclusion: CEP17 multiplication was identified as a promising prognostic marker in patients with invasive breast cancer exhibiting either non-amplified HER2 or normal TOP2A status.
URI
http://hdl.handle.net/YU.REPOSITORY/29600http://dx.doi.org/10.4048/jbc.2012.15.1.24
ISSN
1738-6756
Appears in Collections:
의과대학 > 병리학교실 > Articles
의과대학 > 영상의학과학교실 > Articles
의과대학 > 내과학교실 > Articles
의과대학 > 성형외과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE